浼ユ骞朵锋ц╋

杞诲(Translational Medicine)锛 骞存ュ虹涓涓版蹇点瀹虹锛浠ュ虹绌跺涓村娌荤涓ラ辫筹渚濡ㄧ斤璐璐ｇ缁垂浣跨ㄧ瀵璞绔娉浜哄锛澶ч绁ㄧ镐涓锛琛ㄧ绉璁烘纭瓒ヨ澶锛繁村虫敞骞寸村绛剧杩病寰版娉锛浜冲瑰灞杞诲锛淇杩绉杞涓烘不规

充杞诲锛ュ搴楂渚瀛锛浼モ灞

浼ョ涓浠

寰澶浜轰ラ锛浼ユ骞朵锋ц╋寮ㄤ不蹇╋涓村璇楠缁涓濂斤瀹ｅ澶辫触

ф甯哥搴姝璇楠锛澶╁交搴搴寮锛瑕姹璇楠浜轰氦╀姣缁锛澶ч锋х浜烘缁浜ゅ╋骞舵ョ佃锛寮虹璁璇磋藉锛

杞诲ㄩㄧ绉瀛绌朵寰涔锛缁浜瑙ｅ扳浼モ杩涓╄界跺蹇娌″ユ锛浣存涓涓濂寮琛绠°杩涓ㄢ瀵圭锋у璧峰介纰濂锛浣濂斤涔濂解锛璋ㄨラ

ラ棰瀵煎ぇ涓烘锛存涓村璇楠瀵硅薄瀵圭剧绫诲锛浼间伴辨婧涓杩琚㈢浜澶у灏辩ラ浜锛浼ュ锋х剧纭★杩涓╅杞诲ㄩㄥㄢ椋″ㄧ

ワ绉浜哄浼ユ寰澶扮姣濡锛扮绌惰〃ヨ芥╀绘剧浼璋轰汉锛椋┈涓稿

辨瑙, 涓涓╃ㄥㄤ涔浜轰锛濡浣璁╂村浜哄锛ㄥ澶х瀛瀵规甯搁瑙锛涓虹存崇郴板舵剁

浠涔ㄥㄤ涔浜鸿韩涓锛

杩渚挎杞ㄩㄧ璐ｃ

涓㈡浠氨浠ユ╀负渚瀛锛浜瑙ｄ涓娆х杞诲ㄩㄣ涓璇ラㄩㄧ缁缁缁绉版寰澶т锛 浣璐ｅぇ灏

杞诲ㄩㄤ绌堕ㄩㄦ拌涓昏璐璐ｄ浜涓村璇楠锛ㄥ寸浜哄纭╁ㄦ╄浆ヤ氦缁涓娓搁ㄩㄧ村涓涓村璇楠缁浜у娉ㄥ

涓村璇楠韩卞婚㈠蜂ц锛浣杞诲ㄩㄨ璐ｈ璁′复搴璇楠规锛ｆ峰版堕锛褰惰瑕渚璧杞诲ㄩㄧ澶锛ユ涓村诲澹╁瀹躲瀛缁璁″版朵杈╀汉绛锛浠浠卞瑙ｅ虫釜拌介瑕㈠涓涓揩锛涓㈡浠妇渚璋璋

拌缁浜轰娇

姣釜╁ㄥ濮舵, 戒纭, 淇璇ｈ姹(搴璇锛涓跺杩涓共锛)

浣╁姝ｈ杩ヤ复搴瀹楠舵讹灏辫藉╁板朵绫诲锛姣濡瀵硅虹戒界ㄥㄨ涓锛杩蜂归㈣借村浜哄锛涓归璁╄村揩跺璐电村缁╃

姝ゅ锛╀颁甯瑕灏骞村浣骞寸堕达涓涔村ㄦ绔浜锛寮濮纭板ュ藉凡缁瑕杩涓╀浜洪╂浆诲涓澶存稿浜㈢╃虹锛涔风版э涓虹绉绫诲ㄦお澶浜

杩涓瑰挨涓哄抽浠浠瑕绌惰璇ョ浜虹杩瑕绌惰界璋ㄣ

浠妇涓涓磋╃卞濡(Erbitux)渚瀛 卞濡ユ〃垮瀛浣(EGFR)浣, ㄤEGFR杩〃杈剧缁磋浣绌跺锛濡浜虹缁ユ涓涓KRAS绐锛ｇ卞濡ュ氨姝ゅ荤界娌℃KRAS绐浜轰娇ㄧ卞濡ャ

や浜烘宸ㄥぇ锛涓归涓村璇楠剁浜虹搴浼姣杈楂锛瀹规寰灞瑰锛涓浜烘扮稿锛浠ヨ寰澶寮锛涓归讳浜哄浠ラ垮娌℃寮讹KRAS哄缁磋浜轰ㄦ垮卞濡ュ甫ョㄥ借瀹璐电娌荤堕达浠浠浠ュ灏璇跺芥┿

拌璇ュ浣跨

浣跨ㄥ绉╃ㄧ娌荤涓甯搁瑕锛

绗锛ㄤ涓澶跺涓藉ㄦ惰跨ょ匡姝ら瑕涓╃缁

绗锛浣跨ㄨ╃甯稿浠ラ浣涓杩瀵逛ｄ寰澶уㄧ╁挨堕瑕锛浠ユ捐楂浜虹娲昏川

绗锛╃跺浠ュэ澧浜虹瀛堕淬

ㄨ归妇涓涓瓒ｇ渚瀛锛跺╁缃灏肩(Zelboraf)瀵规BRAF哄绐榛茬ゆ涓锛稿BRAF哄绐磋存娆浣炽

杞诲ㄧ绌朵汉杩瀵逛袱绉杩琛瀵规锛磋ф变楂琛ㄨ揪EGFR瀵艰淬卞濡ユ瀵EGFR浼绉跺┿浠ヨ界跺缃灏肩卞濡ュ芥病锛浣涓よ缁璧锋ョ跺锛 渚垮BRAF哄绐磋璧蜂浣ㄣ

拌娇ㄥ虹浜у浣瑙ｅ筹

涓虹缁寰寮虹绐藉搴藉锛缁澶у伴跺╃浣跨ㄩ戒垮颁拌ч跺涓锛у氨虹浜锛璐逛涔浜烘ョ拌氨涓璧蜂ㄤ锛浜哄璧风甯灏辩寸锛

骞歌杩瀵逛骇х跨ゆ锋ㄨ跨ゆ锋琛哄瀵规锛浠浜寰澶х虹锛骞惰借琛稿娌荤

浠户缁跨磋璇翠锛㈡帮卞濡ュㄦ病KRAS绐磋浜鸿韩涓涓瀹锛浣娌荤涓娈垫堕村浜轰垮浼虹с

杞诲ㄩㄧ绌跺灏杩40%跨や腑虹浜KRAS绐锛姝ょ卞濡ヤ讹绌跺杩涓跺浣跨ㄥ涓绉ㄤ不榛茬ょ跺╋茬垮凹跺(Mekinist)锛璁稿浠ュ磋卞濡ヨэ杩涓复搴璇楠姝ｅㄨ琛涓

杞诲瀵规拌瑕浣杩琛浜洪┿ 娴璇╃绌惰虹杩绋婊℃哄瓒ｅ筹娆㈣村╁瀹朵滑ュ拌浆诲杩涓浠ュぇ灞瀹剧娌块靛帮绂村浜哄浠浠瀹跺涵

锛浣锛娣锛ㄥぇ瀛╃郴锛缇界逛澶у绯诲澹锛娓ぇ瀛╃郴锛缇芥澶у╁澹

璧

[1]Ramdani G, et al. cAMP-Signalling Regulates Gametocyte-Infected Erythrocyte Deformability Required for Malaria Parasite Transmission. PLoS Pathog. 2015 May 7;11(5):e1004815.

[2]Karapetis CS, et al. K-ras mutations and benefit from cetuximab in

advanced colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1757-65.

[3]Prahallad A, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012 Jan 26;483(7387):100-3.

[4]Ahronian LG, et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov. 2015 Apr;5(4):358-67.